Industry

Digital, software and AI for medical device manufacturers

Where the documentation is the product as far as a regulator is concerned, and post-market surveillance never ends.

Medical device manufacturing is a documentation discipline with a factory attached. The European Medical Device Regulation requires technical documentation that must be maintained, updated and producible for years, and post-market surveillance obligations mean the file is never finished.

For a mid-sized manufacturer, that obligation frequently falls on a quality team using shared drives and spreadsheets, which is where the recoverable effort in this sector actually is.

Why this sector is moving now

MDR raised the documentation and evidence bar substantially over the regime it replaced, and many manufacturers found products they had sold for years required significantly more clinical evidence to remain on the market.

Unique Device Identification requirements mean devices carry identifiers that must be registered and traceable through distribution, which turns traceability into an external data obligation rather than an internal record.

Post-market surveillance is continuous. Complaints, incidents and literature all feed a file that must be reviewed and updated on defined cycles, and doing that manually is where quality teams lose their weeks.

The pressures behind it

Technical documentation maintenance: Files that must be current and producible rather than assembled once.
Clinical evidence requirements: A raised bar that put existing products at risk of withdrawal.
UDI and traceability: Device identifiers registered externally and traceable through distribution.
Post-market surveillance: Continuous complaint, incident and literature review on defined cycles.
Restricted promotion: Claims limited to intended purpose, with professional and public audiences treated differently.
Notified body capacity: Certification timelines outside the manufacturer's control and frequently long.

Where the work usually starts

The systems and channels a medical device manufacturers typically needs joined up. Most engagements begin at one spoke and widen only if it earns it.

Usually post-market surveillance data consolidation, because complaints, incidents and literature arrive in different formats through different routes and are assembled by hand into a file with a deadline.

Document control and technical file management follow. We work around the validated quality system rather than inside it, and we are explicit about that boundary from the first conversation.

Marketing and brand for medical device manufacturers

Brand Strategy & Development: Device positioning is constrained to intended purpose, which limits claims sharply. What differentiates commercially is usually clinical evidence, service model or supply reliability, and those are statements that survive regulatory review.
Brand Management: Labelling, instructions for use and packaging are regulated artefacts with prescribed content, produced under change control. Brand consistency here is a document control question with a visual dimension rather than the reverse.
Social Media Strategy: Professional audiences and corporate communication. Public promotion of devices is restricted in most markets and varies by device class, which narrows the workable ground considerably.
Social Media Management: Vigilance obligations mean a comment describing a device problem may constitute a complaint requiring investigation and reporting. Monitoring and escalation must exist before an account does.
Content Creation & Creative Production: Clinical and technical content produced under review, with claims traceable to evidence in the technical file. Timelines have to accommodate review honestly rather than optimistically.
Digital Marketing: Audiences are small, specific and professional — procurement teams, clinicians, distributors. Precision matters and reach metrics describe almost nothing useful in this sector.
Paid Advertising: Restricted for devices requiring professional use, and platform policies add their own limits. Corporate, recruitment and distributor-facing advertising is generally the workable ground.
Search Engine Optimisation: Technical and clinical content for professional searches, plus distributor and procurement information. Claims are constrained, and unreviewed clinical content is a regulatory liability rather than a marketing risk.
Email, SMS & WhatsApp Marketing: Professional and distributor communication rather than consumer marketing. Field safety notices are a separate regulated communication with prescribed timing and content.
Lead Generation & Prospecting: B2B prospecting to hospitals, procurement groups and distributors is a genuine motion with long cycles and identifiable targets. Not applicable to patients or clinicians in a promotional sense.

IT, software and AI for medical device manufacturers

Website Design & Development: Frequently multiple audiences with different regulatory positions — professional, patient, distributor — which in practice means gated sections and audience declaration rather than one open site.
CRM & Sales Systems: Distributor and hospital relationships with long procurement cycles and tender processes. Transparency obligations on interactions with healthcare professionals apply in several markets and shape what must be recorded.
Business Process Automation: Complaint intake and triage, document routing for review, training records, supplier qualification and post-market report assembly. All outside the validated system and all currently manual in most manufacturers.
AI Automation Systems: Literature screening support for post-market surveillance and complaint classification, both with human review. Anything affecting a safety determination or a regulatory conclusion is out of scope for us.
AI Knowledge Bases & RAG: Standards, regulatory guidance, technical files and past submissions, retrievable with citations. In a sector where every answer must trace to a controlled document, source referencing is the requirement rather than a feature.
AI Voice & Customer Communication: Very limited. Anything that might receive a complaint or an adverse incident report needs a person, because those trigger regulatory obligations with deadlines.
Custom Software & Platforms: Justified in the non-validated layer — distributor portals, reporting tools, surveillance dashboards. Software that is itself a medical device is a regulated product and an entirely different undertaking.
Data Engineering & BI: Complaint trends, field performance, distribution and traceability reporting, with lineage documented because conclusions feed regulatory files. Traceability is the requirement that shapes the model.
Cloud, DevOps & Infrastructure: Validation and change control apply to infrastructure supporting quality systems. We generally work alongside that estate rather than inside it and are clear about where the boundary sits.
Systems Integration: QMS to document control, complaints to surveillance, UDI to distribution records, ERP to traceability. Audit trail is the property that matters most; an untraceable transformation is unusable here.
Digital Transformation Consulting: The audit usually finds post-market surveillance and technical file maintenance consuming quality team capacity that could be recovered without touching a validated system.
Maintenance & Ongoing Support: Regulatory requirements and standards update, and surveillance obligations are continuous with defined cycles. Maintenance here has deadlines attached rather than service levels.

What is specific to this sector

The Medical Device Regulation requires technical documentation that is maintained and current rather than assembled for certification, with post-market surveillance feeding back into it on defined cycles. A document system in this sector is therefore a live regulatory instrument, and version control, approval records and retrieval speed are compliance properties rather than conveniences.

Unique Device Identification requires devices to carry identifiers registered in the European database and traceable through the distribution chain. That places an external data obligation on manufacturers that internal record-keeping alone does not satisfy.

Software can itself be a medical device where it has a medical purpose, with classification driving the regulatory pathway. We do not develop regulated device software, and where a proposed feature might cross that boundary we would say so early rather than discover it during a conformity assessment.

EUDAMED, the European database on medical devices, holds registration, UDI, certificate and vigilance information across defined modules, with manufacturers responsible for the accuracy of what they submit. That places an external data quality obligation on internal records, since the database reflects what the manufacturer's systems produced.

Vigilance reporting for serious incidents carries defined deadlines running from the point of awareness, which makes the date a complaint was received a regulatory fact rather than an administrative detail. Complaint intake systems therefore need reliable timestamping and escalation, because a report that misses its deadline is a finding regardless of the eventual conclusion.

Interactions with healthcare professionals are subject to transparency and anti-inducement rules that vary by market, and in some jurisdictions transfers of value must be disclosed. CRM systems used by device sales teams have to record those interactions in a form that supports disclosure, which is a requirement most generic sales tools do not anticipate.

Not legal or regulatory advice. Sector rules described here are scoping context, current to our latest review. Confirm what applies to your business with a qualified adviser.

Questions

Do you develop medical device software?

No. Software with a medical purpose is a regulated product requiring conformity assessment and a specialist development supply chain. We work in the non-validated layer around it — surveillance, documents, distribution, reporting — and we say so rather than take work that should go elsewhere.

Where is recoverable effort under MDR?

Almost always post-market surveillance and technical file maintenance. Complaints, incidents and literature arrive in different formats and are assembled by hand into a file with a deadline, every cycle.

Can AI help with literature screening?

As a screening and prioritisation aid with human review, yes, and it addresses a genuine burden. The determination stays with a qualified person, and we would build it to make that boundary explicit rather than implicit.

What can we say in marketing?

Claims are limited to intended purpose and must be supported by evidence in the technical file. Public promotion is restricted depending on device class, which leaves professional, corporate and distributor communication as the main ground.

What about complaints arriving through social media?

They may constitute complaints requiring investigation and potentially reporting. That means monitoring and escalation processes must exist before an account is opened, which is a point most agencies miss.

How long must technical documentation be retained?

Years after the last device is placed on the market, with the exact period set by regulation and device type. Retention is a design constraint on any system holding it.

What does it cost?

Quoted per phase after a discovery call, with review and documentation overhead scoped explicitly rather than absorbed into an optimistic timeline.

Why does complaint timestamping matter so much?

Because vigilance deadlines run from awareness, so the moment a complaint was received is a regulatory fact. An intake process that loses or approximates that date creates a reporting exposure independent of whether the device had a problem.

Does EUDAMED change how we manage data?

It makes internal data quality externally visible, because what appears in the database is what your systems produced. Registration, UDI and certificate information that was adequate internally frequently needs tightening once it is submitted and attributable.

Can our CRM handle transparency obligations?

Generic sales tools rarely anticipate recording transfers of value or interactions with healthcare professionals in a disclosable form. It is usually a configuration and process question rather than a new system, but it does need addressing deliberately.

Can one website serve both professionals and patients?

Only with a clear separation, because the regulatory position differs by audience and device class. In practice that means audience declaration or gated sections rather than one open site, and it is far cheaper designed in than added afterwards.